Hmm - what do you make of this? On the surface, having the Founder/CSO move on seems to clearly indicate that his skill set is not what is needed right now. That seems to clearly indicate that SGYP will stay a one drug company and not develop new drugs.
This gives credence to the theory that SGYP is already for sale.
Before anyone else jumps in, clearly you also don't need a CSO if the strategy was to be a one-drug company (Trulance) and go it alone in the market, but that is a difficult position to sustain. BP companies with more reps selling multiple products will always be able to outsell you. I think if the strategy was to go it alone long term on Trulance, part of that strategy could include reinvestment in new drugs and research.
I think we have another tell that SGYP is for sale and will be sold as soon as scripts demonstrate enough traction.
News 
Market Data 
Discover 
AI
